On December 18, 2020 Scandion Oncology reported it is currently evaluating its lead candidate SCO-101 in two clinical trials, one with drug resistant metastatic colorectal cancer and one as first line treatment in patients with inoperable pancreatic cancer (Press release, Scandion Oncology, DEC 18, 2020, View Source;scandion-oncology-tackles-antioestrogen-resistance,c3256684 [SID1234574544]). However, last week, the company presented a poster at the San Antonio Breast Cancer Symposium, which is the largest yearly breast cancer meeting. The poster describes the ability of SCO-101 to re-sensitise antioestrogen resistant breast cancer cells. BioStock reached out to Scandion Oncology CMO Peter Michael Vestlev and CTO Jan Stenvang to learn more about this work and its potential implications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!